By: Adel Wilson
SPAIN – With age, the macula, a thin layer of the retina, begins to degenerate and eventually leads to vision loss. In some people, however, this degeneration begins long before they age as it caused by genetic inheritance. This disease is known as retinitis pigmentosa and it causes blindness around 40 years of age and for which there is currently no cure.
“People who suffer from macular degeneration or retinitis pigmentosa have an intact optic nerve. Therefore, could stimulate through innovative, flexible implants that are well adapted to the curvature of the retina, of materials based on graphene, highly biocompatible, so that the optic nerve managed to capture images of the outside “, said José Antonio Garrido , ICREA research professor at the Catalan Institute of Nanoscience and Nanotechnology (ICN2), during the presentation of the new line of work dedicated to biomedical technologies which is inaugurated within the framework of the ambitious European project Graphene Flagship.
These retinal implants are one of the possible and promising applications of graphene and other two – dimensional materials. This is because of their fineness where they have the minimum possible size. In the case of graphene, an atom – thick layer which makes them have much more area to volume ratio. Due to their properties, these new materials could have many therapeutic biomedical applications, which are those that new initiative will explore.
“In the next four years we will try to develop new implants, which provide properties that until now did not exist and that allow us to monitor from epilepsy, to treat Parkinson’s disease or severe depression that does not refer to drugs,” said Garrido…….
Read more: http://www.newslodi.com/life-science/141418-graphene-research-in-the-field-of-biomedicine-treating-retinitis-pigmentosa
Source: News Lodi
By: Adel Wilson